For the cumulative third quarter period (2026\/1\/1\u20132026\/9\/30), non-operating income of 12 million yen and non-operating expenses of 19 million yen were recorded. Main factors include foreign exchange gains and interest income. The impact is as stated in the Financial Summary for the third quarter of the fiscal year ending December 2026 [Japanese GAAP] (non-consolidated). The same amounts of income and expenses were also recorded for the period July 1, 2026\u2013September 30, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"Oncolys BioPharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4588-20261106-02.pdf","jir_short_summary":"For the cumulative third quarter period (2026\/1\/1\u20132026\/9\/30), non-operating income of 12 million yen and non-operating expenses of 19 million yen were recorded. Main factors include foreign exchange gains and interest income. The impact is as stated in the Financial Summary for the third quarter of the fiscal year ending December 2026 [Japanese GAAP] (non-consolidated). The same amounts of income and expenses were also recorded for the period July 1, 2026\u2013September 30, 2026.","jir_summary":"### Overview\nFor the cumulative third quarter period of the fiscal year ending December 2026 (January 1, 2026\u2013September 30, 2026), non-operating income of 12 million yen and non-operating expenses of 19 million yen were recorded. Major income items were interest income received and foreign exchange gains; expenses were due to interest expense paid and amortization of stock-based compensation, among others. The amounts of impact are described in the separately published Financial Summary.\n\n### Future Impact and Notes\nThis matter is disclosed as stated in the Financial Summary published on November 6, 2026. Non-operating profit and loss may fluctuate going forward depending on foreign exchange movements and interest rate trends.","jir_financial_highlights":"Non-operating income: 12 million yen (Breakdown: Interest income received 8 million yen, Foreign exchange gains 3 million yen (from revaluation of foreign-currency denominated assets))\nNon-operating expenses: 19 million yen (Breakdown: Interest expense paid 12 million yen, Amortization of restricted stock compensation 4 million yen, Others)","jir_category":"","jir_hashtags":"#OncolysBioPharma, #NonOperatingIncomeAndExpensesInEarnings, #NonOperatingIncomeExpenses","jir_key_figures":"Non-operating income: 12 million yen\nNon-operating expenses: 19 million yen\nPeriod: 2026\/1\/1\u20132026\/9\/30 (cumulative third quarter period)\nIncome breakdown: Interest income received 8 million yen, Foreign exchange gains 3 million yen\nExpense breakdown: Interest expense paid 12 million yen, Amortization of restricted stock compensation 4 million yen","jir_meta_title":"Oncolys BioPharma Inc. \u2014 Notice of Non-operating Income and Expenses Recorded | November 2026","jir_meta_description":"Oncolys BioPharma Inc. reports recognition of 12 million yen in non-operating income and 19 million yen in non-operating expenses for the cumulative third quarter of 2026. Breakdown includes interest income and foreign exchange gains, as well as interest expense and stock-based compensation amortization. See the Financial Summary for details.","jir_og_title":"Oncolys BioPharma Inc. \u2014 Notice of Non-operating Income and Expenses Recorded | November 2026","jir_og_description":"Oncolys BioPharma Inc. recorded 12 million yen in non-operating income and 19 million yen in non-operating expenses for the cumulative third quarter of 2026. Foreign exchange gains and interest income were primary factors. Detailed information is available in the Financial Summary.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-144033","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n